drugset
drugset / Trial / NCT04539652

Clinical Trial to Evaluate the Efficacy and Safety of TenofoBell® Tablet in Chronic Hepatitis B Patients

NCT04539652 ↗

Phase 4 Completed 78 enrolled Chong Kun Dang Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

This study was designed to evaluate the rate of subjects with HBV DNA less than 20 IU/mL after taking TenofoBell® tablet for 48 weeks

Timeline

Start
2018-09-20
Primary completion
2021-06-22
Completion
2021-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject TenofoBell Unknown — —

Indications

chronic hepatitis B virus infection